Navigation Links
Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
Date:9/4/2007

The largest-ever study of treatments for type 2 diabetes has shown that a combination of two blood pressure lowering drugs reduced the risk of death, as well as the risks of heart and kidney disease. The ADVANCE (Action in Diabetes and Vascular Disease) Study was led by researchers at The George Institute for International Health in Sydney and the results have been presented at the European Congress of Cardiology in Vienna.

One of the study leaders, Professor Stephen MacMahon, Principal Director of The George Institute, said "These results represent an important step forward in the care of people with type 2 diabetes worldwide. This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, and could potentially save several millions of lives over the next decade if the treatment was widely implemented.

More than 600,000 Australians and more than 250 million people worldwide have type 2 diabetes, and most will eventually die or be disabled by the complications. The most common cause of death is heart disease, but kidney disease also affects a large proportion. In 2006, the United Nations called for increased international action to combat the global epidemic of diabetes.

More than 11,000 patients with type 2 diabetes in 20 countries world wide participated in the 4.3 year project. Half received daily treatment with a single tablet containing a fixed combination of two blood pressure lowering drugs (perindopril plus indapamide) and half received matching inactive placebo.

Importantly, the ADVANCE results showed that patients with type 2 diabetes benefited from this blood pressure lowering treatment irrespective of whether or not their blood pressure was elevated to begin with, said study investigator, Dr Bruce Neal, of The George Institute,

The participants in ADVANCE were already receiving most of the usual treatments provided to patients with diabetes, including other drugs to lower blood pressure, explained Dr. Anushka Patel, of The George Institute and the ADVANCE Study Director. However, the addition of the fixed combination of perindopril and indapamide reduced the risk of death from any cause by 14% and the risk of death from cardiovascular disease by 18%. Over 5 years, this treatment would prevent one death among every 80 patients treated.

The results clearly demonstrate that we have the tools to blunt the impact of the global diabetes epidemic facing rich and poor countries alike. But concerted action is urgently required to ensure that patients with diabetes are identified and provided with treatments proven to improve important outcomes like survival, added Professor John Chalmers, the author of international guidelines for the treatment of high blood pressure and chairman of the study management group.


'/>"/>

Contact: Janet Hall
janethall@bigpond.com
61-411-187-808
Research Australia
Source:Eurekalert

Related medicine news :

1. International community warns India on HIV situation
2. Key step forward on International Health Rules
3. ICMR along with other International Research organisation with drug development for Neglected Diseases
4. International Osteoporosis Research Centre To Be Started In India.
5. Indian hospitals require International Accreditation
6. International Conference On Malaria - Laveran To Genomics
7. Delhi To Host International Women’s Congress From Nov 2
8. International conference on Ayurveda to be held on Kerala
9. International Teleradiology: The Future Of Radiologic Diagnosis
10. John Mendelsohn M.D, chosen for an International Award
11. Thailand To Procure Botulism Antitoxin Internationally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
(Date:4/28/2017)... FL (PRWEB) , ... April 28, 2017 , ... ... Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub ... is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The ... retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology: